MMSI
Merit Medical Systems Inc
$
87.540
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
89.320
Open
88.860
VWAP
87.02
Vol
1.45M
Mkt Cap
5.19B
Low
83.040
Amount
125.91M
EV/EBITDA(TTM)
18.70
Total Shares
58.11M
EV
5.53B
EV/OCF(TTM)
20.67
P/S(TTM)
3.59
Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
388.26M
+9.32%
0.951
+2.29%
379.20M
+6.71%
0.907
+5.48%
406.62M
+6.32%
1.063
+5.23%
Estimates Revision
The market is revising Downward the revenue expectations for Merit Medical Systems, Inc. (MMSI) for FY2025, with the revenue forecasts being adjusted by -0.01% over the past three months. During the same period, the stock price has changed by 2.53%.
Revenue Estimates for FY2025
Revise Downward
-0.01%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.03%
In Past 3 Month
Stock Price
Go Up
+2.53%
In Past 3 Month
8 Analyst Rating
Wall Street analysts forecast MMSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MMSI is 102.50 USD with a low forecast of 95.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 87.540
Low
95.00
Averages
102.50
High
108.00
Current: 87.540
Low
95.00
Averages
102.50
High
108.00
Barrington
Outperform
maintain
$103 -> $106
2025-10-31
New
Reason
Barrington
Price Target
$103 -> $106
2025-10-31
New
maintain
Outperform
Reason
Barrington raised the firm's price target on Merit Medical to $106 from $103 and keeps an Outperform rating on the shares after the company reported "strong" Q3 results and increased its FY25 guidance "materially."
Piper Sandler
Overweight
maintain
$105 -> $109
2025-10-31
New
Reason
Piper Sandler
Price Target
$105 -> $109
2025-10-31
New
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Merit Medical to $109 from $105 and keeps an Overweight rating on the shares. The firm notes the company announced Q3 results that once again beat at both the top and bottom lines with 8% organic revenue growth and 9c EPS beat, but it may have been the gross margin upside in Q3 that was most impressive in the period. Full year guidance was raised as well, but in typical Merit Medical fashion Piper sees the implied guide for Q4 as being set in a prudent/responsible way.
Baird
David Rescott
Outperform
maintain
$102 -> $103
2025-10-31
New
Reason
Baird
David Rescott
Price Target
$102 -> $103
2025-10-31
New
maintain
Outperform
Reason
Baird analyst David Rescott raised the firm's price target on Merit Medical to $103 from $102 and keeps an Outperform rating on the shares. The firm updated its model following impressive Q3 results but where volatility remains ahead of its TPT update.
Canaccord
John Young
Buy
maintain
$103 -> $104
2025-10-16
Reason
Canaccord
John Young
Price Target
$103 -> $104
2025-10-16
maintain
Buy
Reason
Canaccord analyst John Young raised the firm's price target on Merit Medical to $104 from $103 and keeps a Buy rating on the shares. The firm updated its model following the announcement of a proposed acquisition from PENTAX Medical pf its C2 CryoBalloon Ablation System; a focal ablation system that expands Merit's Endoscopy product portfolio and will complement its acquisition of Endogastric Solutions that it made last year.
Piper Sandler
Jason Bednar
Overweight
maintain
$106 -> $110
2025-05-23
Reason
Piper Sandler
Jason Bednar
Price Target
$106 -> $110
2025-05-23
maintain
Overweight
Reason
Piper Sandler analyst Jason Bednar raised the firm's price target on Merit Medical to $110 from $106 and keeps an Overweight rating on the shares. The firm is updating its Merit Medical model for several recent items, including the Biolife transaction announced earlier this week and the segment revenue recasting that was done effective Q1.
Wells Fargo
Overweight
maintain
$106 -> $108
2025-05-21
Reason
Wells Fargo
Price Target
$106 -> $108
2025-05-21
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Merit Medical to $108 from $106 and keeps an Overweight rating on the shares. The firm notes the company has announced it acquired hemostasis products, StatSeal and WoundSeal, from BioLife for $120M in cash or about 6.7-times forward year sales. The deal is expected to add $10M-$11M in revenue and be a penny dilutive to EPS in FY25.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Merit Medical Systems Inc (MMSI.O) is 23.64, compared to its 5-year average forward P/E of 26.07. For a more detailed relative valuation and DCF analysis to assess Merit Medical Systems Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
26.07
Current PE
23.64
Overvalued PE
29.47
Undervalued PE
22.68
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
17.86
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
19.61
Undervalued EV/EBITDA
16.11
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
3.69
Current PS
87.54
Overvalued PS
8.81
Undervalued PS
-1.43
Financials
Annual
Quarterly
FY2025Q3
YoY :
+13.04%
384.16M
Total Revenue
FY2025Q3
YoY :
+14.36%
42.61M
Operating Profit
FY2025Q3
YoY :
-2.42%
27.76M
Net Income after Tax
FY2025Q3
YoY :
-4.17%
0.46
EPS - Diluted
FY2025Q3
YoY :
+37.69%
51.51M
Free Cash Flow
FY2025Q3
YoY :
+4.68%
48.52
Gross Profit Margin - %
FY2025Q3
YoY :
+5.91%
13.80
FCF Margin - %
FY2025Q3
YoY :
-13.74%
7.22
Net Margin - %
FY2025Q3
YoY :
-18.62%
6.47
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
3.0M
USD
6
6-9
Months
14.2M
USD
12
0-12
Months
5.1M
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
3.8K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
2
9.1K
Volume
Months
0-12
4
330.7K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
8.0K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
8.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
3.0M
USD
6
6-9
Months
14.2M
USD
12
0-12
Months
5.1M
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
MMSI News & Events
Events Timeline
2025-10-30 (ET)
2025-10-30
16:16:24
Merit Medical increases FY25 EPS forecast to $3.66-$3.79, up from $3.52-$3.72
2025-10-30
16:15:00
Merit Medical announces Q3 earnings per share of 92 cents, surpassing consensus estimate of 83 cents.
2025-10-15 (ET)
2025-10-15
16:11:27
Merit Medical to Purchase C2 CryoBalloon Device for $22 Million, Anticipates Dilution
Sign Up For More Events
Sign Up For More Events
News
4.0
10-31BenzingaPiper Sandler Maintains Overweight Rating on Merit Medical Systems, Increases Price Target to $109
4.0
10-31BenzingaAnalysts' Perspectives on Merit Medical Systems
4.0
10-31BenzingaNeedham Affirms Buy Rating for Merit Medical Systems, Keeps $108 Price Target
Sign Up For More News
People Also Watch
GPI
Group 1 Automotive Inc
397.540
USD
+0.44%
TAL
TAL Education Group
12.260
USD
-5.03%
COLB
Columbia Banking System Inc
26.800
USD
+3.00%
QFIN
Qfin Holdings Inc
24.150
USD
+13.43%
SRAD
Sportradar Group AG
25.610
USD
+0.47%
LEGN
Legend Biotech Corp
32.400
USD
+0.47%
ELAN
Elanco Animal Health Inc
22.150
USD
-1.86%
ETSY
ETSY Inc
62.000
USD
+0.11%
FAQ
What is Merit Medical Systems Inc (MMSI) stock price today?
The current price of MMSI is 87.54 USD — it has increased 5.42 % in the last trading day.
What is Merit Medical Systems Inc (MMSI)'s business?
What is the price predicton of MMSI Stock?
What is Merit Medical Systems Inc (MMSI)'s revenue for the last quarter?
What is Merit Medical Systems Inc (MMSI)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Merit Medical Systems Inc (MMSI)'s fundamentals?
How many employees does Merit Medical Systems Inc (MMSI). have?